The progranulin (PGRN) is known to protect regulatory T cells (Tregs) from a negative regulation by TNF-α, and its levels are elevated in various kinds of autoimmune diseases. Whether PGRN directly regulates the conversion of CD4+CD25-T cells into Foxp3-expressing regulatory T cells (iTreg), and whether PGRN affects the immunosuppressive function of Tregs, however, remain unknown. In this study we provide evidences demonstrating that PGRN is able to stimulate the conversion of CD4+CD25-T cells into iTreg in a dose-dependent manner in vitro. In addition, PGRN showed synergistic effects with TGF-β1 on the induction of iTreg. PGRN was required for the immunosuppressive function of Tregs, since PGRN-deficient Tregs have a significant decreased ability to suppress the proliferation of effector T cells (Teff). In addition, PGRN deficiency caused a marked reduction in Tregs number in the course of inflammatory arthritis, although no significant difference was observed in the numbers of Tregs between wild type and PGRN deficient mice during development. Furthermore, PGRN deficiency led to significant upregulation of the Wnt receptor gene Fzd2. Collectively, this study reveals that PGRN directly regulates the numbers and function of Tregs under inflammatory conditions, and provides new insight into the immune regulatory mechanism of PGRN in the pathogenesis of inflammatory and immune-related diseases.
Citation: Wei F, Zhang Y, Zhao W, Yu X, Liu C-j (2014) Progranulin Facilitates Conversion and Function of Regulatory T Cells under Inflammatory Conditions. PLoS ONE 9(11): e112110. https://doi.org/10.1371/journal.pone.0112110
Editor: Srinivas V. Kaveri, INSERMU1138, France
Received: July 16, 2014; Accepted: October 13, 2014; Published: November 13, 2014
Copyright: © 2014 Wei et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper.
Funding: This work was supported partly by NIH research grants R01AR062207, R01AR061484, R56AI100901, and a Disease Targeted Research Grant from Rheumatology Research Foundation. The authors state that the funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
CD4+CD25+Foxp3+ regulatory T cells (Tregs) play a critical role in maintenance of peripheral tolerance and prevention of chronic inflammation and autoimmune diseases , . Tregs can be divided into two main types: naturally occurring regulatory T cells (nTreg) and adaptive/inducible regulatory T cells (iTreg). nTreg are generated in thymus and represent a stable subpopulation and suppress the proliferation of self reactive T cells in the secondary lymphoid tissues . In contrast, iTreg are generated in peripheral lymphoid tissues, which have variable expression of Foxp3 and may lose regulatory properties after their generation. Recent studies have shown that iTreg can be differentiated from the conventional CD4+CD25- T cells in the presence of TGF-β . Since iTreg play essential roles in self-tolerance and autoimmunity, an investigation of iTreg induction and function would be of great importance in their therapeutic potential –. A global sequencing revealed that Foxp3 and Wnt target genes are considerably overlapped, suggesting a crucial role of Wnt signaling in Treg function . In addition, stable expression of β-catenin enhanced the survival of Treg cells and rendered pathogenic CD4+CD25- T cells anergic .
Progranulin (PGRN), also called granulin epithelin precursor (GEP), PC-cell-derived growth factor (PCDGF), proepithelin, and acrogranin, is a 593-amino-acid secreted growth factor , . PGRN is known to play an important role in a variety of physiologic and pathological processes, including wound healing, inflammation response, neurotrophic factor, and host defense . PGRN can be induced in many cell types during inflammatory conditions, including immune cells and epithelial cells . PGRN associates with some members in the TNF receptor superfamily, including TNFR1, TNFR2 and DR3 , –, and possesses the ability to suppress inflammation in various kinds of conditions , –. The association between PGRN levels and systemic inflammation and autoimmunity has been reported –, for instance, serum levels of PGRN were elevated in systemic lupus erythematosus and related with disease activity . Auto-antibodies against PGRN have also been found in several autoimmune diseases, including rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease, and such antibodies promoted a proinflammatory environment in a subgroup of patients –. Furthermore, PGRN was found to protect Tregs from a negative regulation by TNF-α , . However, the direct regulation of PGRN on Tregs has not been reported yet. In this study, we present direct evidences that PGRN stimulates Tregs formation and is also required for its immunosuppressive activity.
Materials and Methods
All of the animal studies were performed and approved by the Institutional Animal Care and Use Committee of New York University (IACUC protocol #130202-01). C57BL/6, Foxp3-RFP mice (C57BL/6 background) were obtained from Jackson Laboratories. The generation of PGRN-deficient mice has been described previously . All efforts were made to minimize animal suffering through anaesthesia.
Spleen cells and lymphocytes from wild type and PGRN-deficient mice were stained using antibodies to mice CD4-FITC, CD25-PE and Foxp3-Alex Flour 647 (all from eBioscience, San Diego, CA, USA). Intracellular staining for Foxp3 (eBioscience, San Diego, CA, USA) were conducted according to the manufacturers' instructions. Data were acquired on a LSRII (BD) and analyzed with FlowJo (Tree star, Ashland OR). For CFSE labeling, cells were incubating with 5 mM CFSE (Invitrogen, Carlsbad, CA, USA) in PBS (containing 0.1% BSA) at 37°C for 10 min.
For isolation of CD4+CD25- T cells, 1×107 lymphocytes of spleens from 6- to 8-week-old mice were incubated with 10 µl antibody cocktail (Miltenyi Biotech, Bergisch Gladbach, Germany) and 10 µl anti-CD25 (biotin labeling), followed by incubation with 20 µl anti-biotin microbeads according to the manufactures instructions (Miltenyi Biotech, Bergisch Gladbach, Germany). The purity of the CD4+CD25- T cells was above 95%, as examined by FACS method.
For isolation of CD4+CD25+ T cells, lymphocytes of spleens from 6- to 8-week-old mice were depleted of cells that were labeled with Ab-to-mouse B220 and CD8 by magnetic cell sorting using Mitenyi reagents and a MACS apparatus. Then the lymphocytes were stained with CD4-APC and CD25-PE antibodies, washed 2 times with staining buffer and resuspended with sorting buffer. CD4+CD25+ T cells were sorted by FACS MoFlo cytometer. The purity of sorted fraction was 90–95%.
The recombinant PGRN protein was prepared according to our previous publication . One week-old Foxp3-RFP reporter mice were divided into two groups (n = 3). Two group mice were treated with 100 µg PGRN or PBS (serving as a control) by intraperitoneal injection every two days. After 1 week, the lymphocytes of spleen, peripheral lymph nodes (PLN), mesenteric lymph nodes (MLN), and Peyer's patches (PP) were collected for analysis by FACS.
In vitro naïve CD4+CD25- T cells conversion assay
Naïve CD+CD25- T cells were purified from lymphocytes of spleens from Foxp3-GFP mice (6- to 8-week-old) using Mitenyi reagents and a MACS apparatus according to the manufactures instructions. Naïve cells were stimulated with plate-bound anti-CD3 (10 µg/ml, BD, San Diego, CA, USA) and soluble anti-CD28 (1 µg/ml, BD, San Diego, CA, USA) for 3–4 days in the presence of IL-2 (20 U/ml, R&D, Minneapolis, MN, USA). Human TGF-β (0 ng/ml, 0.01 ng/ml) and recombinant PGRN protein (0 µg/ml, 0.2 µg/ml, 1 µg/ml) were added as indicated. The induction of Foxp3+ T cells in the CD4+ fraction was detected by flow cytometry based on the levels of GFP.
In vitro suppression assay
CD4+CD25- T cells were magnetic sorted from spleen lymphocytes of Thy1.1 mice (C57BL/6 background) using isolation kit from Miltenyi, and labeled with 5 mM CFSE as responder cells (Teff). 1×106 spleen cells from TCRα-/-β-/- mice (C57BL/6 background) were lysed with red blood cell lysis buffer for 3 min, washed with pre-cooling PBS and treated with 1 µg mitomycin for 20 min, then resuspended with RPMI 1640 medium as antigen-presenting cells (APC). CD4+CD25+ T cells were FACS sorted from spleen lymphocytes of wild type and PGRN-deficient mice as suppressor cells.
For the analysis of suppression function, we performed assays in 96-well plate. Each well contained 0.5×105 responder cells, 1×105 mitomycin-treated APC cells and anti-CD3 at a concentration of 5 µg/ml. Suppressor cells were added at suppressor and responder cells rations of 1∶2, 1∶1, 2∶1, 4∶1 and 8∶1. Responder cells proliferation with wild type CD4+CD25+ T cells or PGRN-deficient CD4+CD25+ T cells were analyzed by FACS method assessing CFSE dilution after 3 days.
BrdU incorporation assay
Wild type (n = 3) and PGRN-deficient mice (n = 3) were injected intraperitoneally with BrdU labeling reagent (BrdU, Sigma-Aldrich, St Louis, MO, USA) at a dose of 10 ml/kg body weight and sacrificed 2 hours later. Lymphocytes from spleen and lymph nodes were prepared. Then we performed cell surface staining with CD4-PerCP-cy5.5 and CD25-APC and permeabilized for intracellular staining of BrdU using the BrdU flow kit (BD, San Diego, CA, USA) according to the manufactures instructions.
CD4+CD25+T cells were purified from the splenocytes of both wild type and PGRN-deficient mice by FACS sorting. Total RNA was extracted from CD4+CD25+T cells using RNeasy mini kit (Qiagen, Valencia, CA, USA). 1 µg RNA samples were reverse- transcribed by use of ImProm-II™ Reverse Transcription System (Promega, Madison, WI, USA). The primer pairs and expected length are in Table 1. Relative mRNA expression was measured as the fold increase in expression by 2-ΔΔct method and data was normalized to mRNA levels of GAPDH.
Induction of CIA
Chicken type II collagen (Chondrex, LLC, Seattle, WA) was emulsified with an equal volume of complete Freund's adjuvant (CFA) (Chondrex, LLC, Seattle, WA). Wild type mice (n = 6) and PGRN-deficient mice (n = 6) were intradermally immunized with 100 µl of the emulsion at the base of the tail. After 3 weeks, draining lymph nodes were extracted and CD4+CD25+Foxp3+ cells were analyzed by FACS.
PGRN deficiency does not alter the numbers of CD4+CD25+Foxp3+ Treg cells in vivo
To determine the role of PGRN in the development of naturally CD4+CD25+Foxp3+ cells, we used flow cytometry to analyze the numbers of CD4+CD25+Foxp3+ cells in lymphocytes of thymus, spleen, and lymph nodes from one-, three-, and six-week-old wild type and PGRN-deficient mice. As shown in Fig. 1A, one-week-old wild type and PGRN-deficient mice have comparable proportions of CD4+ and CD8+ T cells in thymus (p>0.05), and no significant difference in the percentage of CD4+CD25+Foxp3+ cells in thymus were found (p>0.05) (Fig. 1B). Equivalent numbers of CD4+CD25+Foxp3+ cells were found in the spleen and lymph nodes in three- and six-week-old PGRN-deficient mice, compared with wild type mice (p>0.05) (Fig. 1C–F). Thus, the results suggest that the absence of PGRN may not affect the generation of naturally CD4+CD25+Foxp3+ cells during development.
Flow cytometric evaluation of CD4+CD25+Foxp3+ T cells in one-, three-, and six-week-old wild type (WT) and PGRN-deficient mice. (A) The percentage of CD4+ and CD8+ T cells in thymus from one-week-old C57BL/6 mice and PGRN-deficient mice. (B) The percentage of CD4+CD25+Foxp3+ cells in thymus from one-week-old C57BL/6 mice and PGRN-deficient mice. (C) The proportion of CD4+CD25+Foxp3+ cells in spleen from three-week-old C57BL/6 mice and PGRN-deficient mice. (D) CD4+CD25+Foxp3+ cells in lymph nodes from three-week-old C57BL/6 mice and PGRN-deficient mice. (E) The proportion of CD4+CD25+Foxp3+ cells in spleen from six-week-old C57BL/6 mice and PGRN-deficient mice. (F) CD4+CD25+Foxp3+ cells in lymph nodes from six-week-old C57BL/6 mice and PGRN-deficient mice. All data was representative of three mice per group and indicated as mean ± SEM.
In a separate experiment, one-week-old Foxp3-RFP mice were treated with 100 µg PGRN every two days for 1 week, and the percentage of CD4+RFP+ cells in lymphoid tissues were analyzed by FACS. The results revealed that the numbers of CD4+RFP+ cells in spleen (15.1±0.8% RFP+ cells in PBS group versus 14.0±0.4% in PGRN group), peripheral lymph nodes (16.1±0.2% RFP+ cells in PBS group versus 16.0±0.1% in PGRN group), mesenteric lymph nodes (15.1±1.0%RFP+ cells in PBS group versus 15.9±1.6% in PGRN group), and Peyer's patches (15.3%±2.0 RFP+ cells in PBS group versus 12.3±1.8% in PGRN group) in these two groups was not significantly changed (p>0.05) (Fig. 2). In brief, these findings demonstrate that PGRN treatment does not change the proportions and numbers of CD4+CD25+Foxp3+ cells under physiological conditions.
One week-old Foxp3-RFP reporter mice were divided into two groups, three mice per group. PGRN group mice were treated with 100 µg PGRN every two days for 1 week, and PBS group mice were injected with the same volume of PBS as a control. The lymphocytes of spleen, peripheral lymph nodes (PLN), mesenteric lymph nodes (MLN), and Peyer's patches (PP) were isolated and analyzed by FACS. All data are representative of three independent experiments.
PGRN promotes the CD4+CD25- T cells conversion into Foxp3-expressing iTreg
Since iTreg cells are essential in immune tolerance and in the prevention of chronic inflammation , growth factors which can boost TGF-β-mediated the conversion of CD4+CD25- T cells into iTreg will be of great importance in inflammatory conditions. TGF-β was reported to induce Foxp3-expressing iTreg . We sought to determine whether PGRN regulates the conversion of CD4+CD25- T cells into iTreg. In a loss-of-function study, we first stimulated naïve wild type and PGRN-deficient CD4+CD25- T cells with plate-bound CD3 antibody and soluble CD28 antibody in the presence of IL-2 and cultured for 3-4 days with or without TGF-β. In the absence of TGF-β, PGRN-deficient CD4+CD25- T cells have comparable capacity to convert into iTreg cells (0.10±0.02% Foxp3+ cells in KO versus 0.12±0.01% in WT, p>0.05) (Fig. 3A). In addition, no difference were found in wild type and PGRN-deficient CD4+CD25- T cells conversion into iTreg cells in the presence of TGF-β at dose of 1 ng/ml (49.8±3.3% Foxp3+ cells in KO versus 48.3±1.0% in WT, p>0.05) and 10 ng/ml (84±1.4% Foxp3+ cells in KO versus 84.3±3.5% in WT, p>0.05) (Fig. 3B-C). Thus, the findings suggest endogenous PGRN may not be required for CD4+CD25- T cells conversion into iTreg.
Naïve CD4+ CD25- T cells isolated from both wildtype (WT) and PGRN-deficient mice were stimulated with plate-bound CD3 Ab and solute CD28 Ab and cultured the cells for 3-4 days in the presence or absence of TGF-β, and the expression of GFP was measured by FACS. (A) The GFP levels in CD4+ T cells in the absence of TGF-β. (B) The GFP levels in CD4+ T cells in the presence of 1 ng/ml TGF-β. (C) The GFP levels in CD4+ T cells in the presence of 10 ng/ml TGF-β. All data were repeated three times with similar results.
We further performed the gain-of-function experiment, we treated CD4+GFP- T cells with different concentrations of PGRN and examined the change of GFP expression in CD4+ T cells. As shown in Fig. 4, PGRN significantly promoted the conversion of CD4+GFP- T cells into CD4+GFP+ T cells at a dose-dependent manner in the presence of 0.1 ng/ml TGF-β (2.74±0.70% GFP+ cells with no PGRN versus 4.33±0.98% GFP+ cells with 200 ng/ml PGRN versus 12.3±2.85% GFP+ cells with 1 µg/ml PGRN, p <0.05) (Fig. 4D–F). Furthermore, in the absence of TGF-β, 1 µg/ml of PGRN significantly induced the expression of GFP in 5.67±1.65% of the cells, when compared with 0.16±0.07% GFP+ cells without PGRN (p <0.01) (Fig. 4A and C). And low concentrations of PGRN also significantly induced GFP expression in CD4+ cells, when compared with no PGRN conditions (0.63±0.23% GFP+ cells versus 0.16±0.07% GFP+ cells, p <0.05) (Fig. 4B). Taken together, these results indicate that recombinant PGRN promotes and synergistically enhances TGF-β-mediated induction of inducible regulatory T cells in vitro.
Naïve CD4+GFP- cells in lymphocytes of spleen from Foxp3-GFP reporter mice were purified by using Mitenyi reagents and a MACS apparatus. The purity of cells was evaluated by FACS method. CD4+GFP- cells conversion assay was performed as described in Methods, and GFP expression in TGF-β-unstimulated CD4+GFP- cells was taken as a control. After 3-4 days, cells were washed and GFP expression was analyzed by FACS. Data represent three independent experiments are shown. (A) No TGF-β and no PGRN. (B) No TGF-β plus 200 ng/ml of PGRN. (C) No TGF-β plus 1 µg/ml of PGRN. (D) 0.1 ng/ml of TGF-β and no PGRN. (E) 0.1 ng/ml of TGF-βplus 200 ng/ml of PGRN. (F) 0.1 ng/ml of TGF-β plus 1 µg/ml of PGRN. Data represent as a means ±SE of a representative experiment. *p<0.05; **p<0.01.
PGRN deficiency decreases the immunosuppressive function of CD4+CD25+ T cells
The proportion of normal CD4+CD25+ Tregs constitutes 5–10% of peripheral CD4+ T cells in mice and 1–2% in humans, and can potently suppress the proliferation of active CD4+CD25- and CD8+ T cells , . To evaluate the role of PGRN signaling in regulation of CD4+CD25+ Tregs function, we performed in vitro CFSE-based proliferation suppression assay. 5×105 CFSE-labeling Teff cells were stimulated for 72 hours with CD3 antibody (5 µg/ml) in the presence of 1×105 APC cells and varying ratios of FACS purified WT or PGRN-deficient CD4+CD25+ Tregs, and CFSE dilution was evaluated by FACS. The CFSE proliferation in negative control and positive control group was 1.93±0.1% and 94.2±3.2%, respectively (Fig. 5A and B). Our results demonstrate that wild type and PGRN-deficient CD4+CD25+ Tregs significantly suppress the CFSE proliferation when Teff co-cultured with Tregs at rations of 1∶2, 1∶1, 2∶1 and 4∶1, compared with positive control group (p<0.05) (Fig. 5B–F). PGRN-deficient Tregs significantly decreased suppressive capacity when Teff co-cultured with Tregs at ratios of 1∶2 (66.3±3.2% CFSE dilution in KO versus 52.5±3.0% CFSE dilution in WT, p<0.01, Fig. 5C) and 1∶1 (79.6±3.78% CFSE dilution in KO versus 65.4±3.6% CFSE dilution in WT, p<0.01, Fig. 5D), compared with wild type Tregs. Suppressor cells were added at suppressor and responder cells rations of 2∶1, PGRN-deficient Tregs showed a slightly lower suppressive capacity than wild type Tregs (80.8±2.18% CFSE dilution in KO versus 75.5±1.5% CFSE dilution in WT, p<0.05, Fig. 5E). However, no significant difference were found between wild type and PGRN-deficient Tregs at ratios of 4∶1 (86.3±1.4% CFSE proliferation in KO versus 83.8±1.7% CFSE proliferation in WT, p>0.05, Fig. 5F) and 8∶1 (89.3±0.1% CFSE dilution in KO versus 87.6±2.0% CFSE dilution in WT, p>0.05, Fig. 5G). Collectively, PGRN is required for the immunosuppressive function of Tregs in vitro.
Freshly isolated, CFSE-labeled CD4+CD25- T cells from Thy1.1 mice were used as Teff and co-cultured with Tregs at ratios of 1∶2, 1∶1, 2∶1, 4∶1 and 8∶1. CFSE-based Teff proliferation suppression assay in vitro in which 5×105 CFSE-labeled Teff cells were stimulated with CD3 antibody in the presence of mitomycin-treated APC cells and different ratios of FACS sorted wild type or PGRN-deficient Tregs. The CFSE proliferation was evaluated by FACS. All data are representative of three separate experiments. (A) Negative control. (B) Positive control. (C) The CFSE dilution when Teff co-cultured with Tregs at ratios of 1∶2. (D) The CFSE dilution when Teff co-cultured with Tregs at ratios of 1∶1. (E) The CFSE dilution when Teff co-cultured with Tregs at ratios of 2∶1. (F) The CFSE dilution when Teff co-cultured with Tregs at ratios of 4∶1. (G) The CFSE dilution when Teff co-cultured with Tregs at ratios of 8∶1. Data represent as a means ±SE of a representative experiment. *p<0.05; **p<0.01.
PGRN deficiency does not affect the proliferation of CD4+CD25+ Treg in vivo
5-Bromo-2-deoxyuridine (BrdU) is a pyrimidine analogue of thymidine, selectively incorporated into replicating DNA, effectively tagging dividing cells. To determine whether PGRN deficiency alters the proliferation of Tregs in vivo, we set a BrdU incorporation assay. We injected BrdU labeling reagent (BrdU, Sigma-Aldrich) at a dose of 10 ml/kg body weight into wild type and PGRN-deficient mice, three mice per group. Mice were sacrificed 2 hours after injection and intracellular staining of BrdU in lymphocytes of spleen (SP) and lymph nodes (LN) were stained with BrdU flow kit (BD Bioscience) and analyzed by FACS. We did not observe any significant changes in the number of CD4+CD25+BrdU+ cells from splenocytes between wild-type and PGRN-deficient mice (6.58±1.42% BrdU+ cells in KO versus 5.68±0.11% BrdU+ cells in WT, p>0.05) (Fig. 6A–B). In addition, 6.54±1.46% of the cells in lymphocytes of lymph nodes are BrdU positive from PGRN-deficient mice, and comparable to 6.58±0.77% BrdU+ cells seen in wild type mice (p>0.05) (Fig. 6C and D). These findings suggest that wild type and PGRN-deficient CD4+CD25+ Treg cells have a comparable proliferation and division capacity in vivo.
Wild type and PGRN-deficient mice were injected intraperitoneally with BrdU labeling reagents, and the degrees of BrdU incorporation by CD4+CD25+ T cells from lymphocytes of spleen and lymph nodes were determined by FACS. (A) The BrdU incorporation of wild type CD4+CD25+ T cells from splenocytes. (B) The BrdU incorporation of PGRN-deficient CD4+CD25+ T cells from splenocytes. (C) The percentage of wild type CD4+CD25+ T cells from lymphocytes of lymph nodes that incorporated BrdU. (D) The percentage of PGRN-deficient CD4+CD25+ T cells from lymphocytes of lymph nodes that incorporated BrdU. All data was representative of three mice per group and indicated as mean ±SEM.
PGRN deficiency leads to fewer Treg cells in collagen-induced arthritis (CIA)
To determine whether the PGRN deficiency alters the number of Tregs in inflammatory conditions, we established a collagen-induced arthritis (CIA) model. Wild type and PGRN-deficient mice, six mice per group, were intradermally injected with 100 µl of the emulsion at the base of the tail. Two group mice were sacrificed 21 days after immunization and intracellular staining of Foxp3 in lymphocytes of draining lymph nodes (LN) was stained and analyzed by FACS. The results demonstrate that PGRN-deficient CD4+CD25- T cells have an impaired ability to generate iTreg in arthritis conditions (Fig. 7A–B). Arthritic PGRN-deficient mice shown a significant changes in the number of CD4+CD25+Foxp3+ cells from draining lymph nodes (11.8±0.2% CD4+CD25+Foxp3+ cells in arthritic KO mice versus 20.4±2.7% CD4+CD25+Foxp3+ cells in arthritic WT mice, p<0.01, Fig. 7A–B). These findings suggest that PGRN deficiency leads to fewer CD4+CD25+Foxp3+ Treg cells in collagen-induced arthritis conditions.
Wild type (n = 6) and PGRN-deficient mice (n = 6) were intradermally immunized with 100 µl of chicken type II collagen emulsified with an equal volume of complete Freund's adjuvant (CFA). 21 days post immunization, draining lymph nodes were extracted and CD4+CD25+Foxp3+ T cells were analyzed by FACS. Data represent as a means ±SE of a representative experiment. **p<0.01.
PGRN deficiency upregulates the expression of Fzd2 in CD4+CD25+ T cells
Wnt signaling proteins can be divided into two subgroups according to the downstream molecules, the canonical pathway which stabilized β-catenin and activated target genes through the regulation of TCF/Lef transcription factors, and the noncanonical pathway did not dependent on the regulation of β-catenin and activated protein kinase C and G proteins, etc . It was reported that Wnt signaling regulated PGRN-mediated frontotemporal dementia (FTD) and PGRN and Wnt reciprocally regulated each other , . Moreover, Wnt signaling was also reported to stabilize the survival of CD4+CD25+ Treg cells and to enhance their suppressive capacity , . To further study the molecular events underlying PGRN-mediated regulation of CD4+CD25+ T cells, we purified CD4+CD25+ T cells from splenocytes of wild type and PGRN-deficient mice by FACS sorting and examined the gene expression of Wnt signaling components through real-time PCR. Our results did not found significantly change of Wnt1, Wnt2, Wnt3a, Wnt4, Wnt5a, Wnt5b, Wnt7a, Wnt8b, Wnt11, Wisp2, Fzd1, Fzd4, Fzd6, Fzd7, Fzd8, Fzd9, Fzd10, β-catenin, TCF1, TCF3, wisp1 and axin2 gene expression (p>0.05) (Fig. 8). Interestingly, the mRNA level of Fzd2 gene in PGRN-deficient CD4+CD25+ T cells was significantly upregulated, when compared with its expression in wild type CD4+CD25+ T cells (p<0.01) (Fig. 8). Collectively, this set of experiments indicated that PGRN deficiency upregulates the expression of Fzd2 gene in CD4+CD25+ T cells.
Inducible CD4+CD25+Foxp3+ regulatory T cells (iTreg) develop outside of the thymus and play an essential role in controlling of chronic inflammation and autoimmunity . Therefore, investigation of the growth factors which can convert naïve conventional T cells into iTreg may provide a new strategy for manipulating chronic inflammation and autoimmune diseases. In this study, we examine the role of PGRN in the conversion of CD4+CD25- T cells into Foxp3-expressing iTreg and immunosuppressive function of CD4+CD25+ Tregs. Our findings demonstrate that PGRN significantly promotes the conversion of naïve CD4+CD25- T cells into iTreg mediated by lower concentration of TGF-β in a dose-dependent manner (Fig. 4D–F). PGRN alone also effectively induce the generation of iTreg, although less efficiently than the conversion capacity induced by TGF-β (Fig. 4A–C). The findings that PGRN alone or combined with TGF-β stimulates the production of iTreg may provide new insights into the conversion of naïve CD4+CD25- T cells into iTreg.
PGRN deficiency does not alter the numbers and percentage of CD4+CD25+Foxp3+ T cells in thymus, spleen, and lymph nodes in different ages of mice (Fig. 1). In addition, mice in PGRN-treated group have a comparable number of CD4+CD25+Fxop3+ T cells in spleen, peripheral lymph nodes, mesenteric lymph nodes, and Peyer's patches, when compared with the PBS group (Fig. 2). However, PGRN deficiency leads to a marked reduction of Treg number in collagen-induced inflammatory arthritis (Fig. 7). These results suggest that PGRN is important for the Tregs formation under inflammatory conditions, and does not influence the development of Tregs under normal immune homeostasis. A deficiency or defective function of Tregs is common in autoimmune diseases such as rheumatoid arthritis . Furthermore, therapeutic agents that target Tregs can benefit rheumatoid arthritis. For instance, intravenous immunoglobulin (IVIg) also induces the expansion of Tregs and enhances their suppressive function and exerts beneficial effect in autoimmune diseases –. In addition, our previous report also supports this concept . In CIA model, PGRN inhibits Th1 (IFNγ) cytokines production in Teff cells, decreases the levels of IL-6 expression in serum, prevents TNFα-induced downregulation of Tregs suppressive function and inhibits inflammatory arthritis in mice .
CD4+CD25+ Tregs potently suppress the proliferation of active CD4+CD25- cells , . In vitro Teff proliferation suppression assay demonstrated that PGRN deficiency led to significant reduction in the suppressive function of Tregs (Fig. 5C–E), indicating an important immunosuppressive role of PGRN in Tregs. PGRN insufficiency resulted from the mutations in the GRN gene was reported to cause reduced survival signaling and accelerated cell death in neurons –. PGRN deficiency does not affect the proliferation of Teff cells (data not show). Therefore, we further investigated the correlation between Tregs function and cell survival in PGRN-deficient mice using BrdU incorporation assay. Interestingly, we did not observe significant difference in CD4+CD25+BrdU+ numbers between wild type and PGRN-deficient mice (Fig. 6A–D), suggesting PGRN-deficiency may not impair Tregs survival and proliferation under normal immune homeostasis in vivo.
It is known that Wnt signaling plays an important role in regulating CD4+CD25+ Tregs. For instance, β-catenin and Wnt3a both regulate Tregs function , , . Fzd2 receptor was reported to be involved in the Wnt3a-dependent activation of β-catenin pathway and also required for Wnt5a-mediated β-catenin-independent pathway . In our study, we found the level of Fzd2 was upregulated in PGRN-deficient Treg cells (Fig. 8). The finding is consistent with a recent report that Fzd2 is upregulated in PGRN-knockout mice using weighted gene coexpression network analysis (WGCNA) . It is postulated that regulation of Fzd2 by PGRN may also contribute to the PGRN-mediated regulation of Tregs.
PGRN associates with some members in the TNF receptor superfamily, including TNFR1, TNFR2 and DR3 , –, and possesses the ability to suppress inflammation in various kinds of conditions , –. Auto-antibodies against PGRN have been found in several autoimmune diseases, including rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease, and such antibodies promoted a proinflammatory environment in a subgroup of patients –. In accordance with the finding that PGRN binds to TNFR, we found that PGRN protected Tregs from a negative regulation by TNF-α . This finding has been also independently confirmed by other laboratories . Chen and colleagues agreed that PGRN played an protective role in Tregs, but through enhancing TNF-α-induced Tregs proliferation . The effect of TNF-α on the regulation of Tregs purified from mice and humans appears to be highly controversial. The data from Chen lab suggest that TNF-α promotes murine Tregs activity in vitro , whereas in humans, TNF-α inhibits the suppressive function of Tregs through negative regulation of Foxp3 expression , –. Although the effect of TNF-α on Tregs function remains controversy, the beneficial and therapeutic effects of Tregs in autoimmune diseases have been well-accepted by the scientific community , . In addition, TNF-α inhibitors have been accepted as the most effective anti-inflammatory therapeutics.
In summary, this study provides evidences demonstrating that PGRN directly regulates the induction of iTreg and function of Tregs in vitro, in addition to its antagonizing TNF-α-mediated negative regulation of Tregs. More importantly, PGRN deficiency leads to a significant reduction in Tregs in the course of inflammatory arthritis in vivo. Additionally, selective and significant upregulation of Fzd2 gene expression in PGRN deficient Tregs may contribute to the PGRN regulation of Tregs. These findings not only provide new insights into the role and regulation of PGRN in Tregs, but also present PGRN and/or its derivatives as therapeutic targets for treating chronic inflammatory and autoimmune diseases.
We thank Dr. Juan Lafaille for providing TCRα-/-β-/- (C57BL/6 background), Thy1.1 (C57BL/6 background), and Foxp3-GFP (C57BL/6 background) mice.
Conceived and designed the experiments: CJL FHW. Performed the experiments: YYZ FHW. Analyzed the data: WMZ XPY CJL. Contributed reagents/materials/analysis tools: YYZ. Wrote the paper: YYZ CJL.
- 1. Takahashi T, Sakaguchi S (2003) Naturally arising CD25+CD4+ regulatory T cells in maintaining immunologic self-tolerance and preventing autoimmune disease. Current molecular medicine 3: 693–706.
- 2. Takahashi T, Sakaguchi S (2003) The role of regulatory T cells in controlling immunologic self-tolerance. International review of cytology 225: 1–32.
- 3. Ouyang W, Beckett O, Ma Q, Li MO (2010) Transforming growth factor-beta signaling curbs thymic negative selection promoting regulatory T cell development. Immunity 32: 642–653.
- 4. Xu L, Kitani A, Strober W (2010) Molecular mechanisms regulating TGF-beta-induced Foxp3 expression. Mucosal immunology 3: 230–238.
- 5. Dons EM, Raimondi G, Cooper DK, Thomson AW (2012) Induced regulatory T cells: mechanisms of conversion and suppressive potential. Human immunology 73: 328–334.
- 6. Schmitt EG, Williams CB (2013) Generation and function of induced regulatory T cells. Frontiers in immunology 4: 152.
- 7. Zhou X, Kong N, Zou H, Brand D, Li X, et al. (2011) Therapeutic potential of TGF-beta-induced CD4(+) Foxp3(+) regulatory T cells in autoimmune diseases. Autoimmunity 44: 43–50.
- 8. van Loosdregt J, Fleskens V, Tiemessen MM, Mokry M, van Boxtel R, et al. (2013) Canonical Wnt signaling negatively modulates regulatory T cell function. Immunity 39: 298–310.
- 9. Ding Y, Shen S, Lino AC, Curotto de Lafaille MA, Lafaille JJ, et al. (2008) Beta-catenin stabilization extends regulatory T cell survival and induces anergy in nonregulatory T cells. Nature medicine 14: 162–169.
- 10. Anakwe OO, Gerton GL (1990) Acrosome biogenesis begins during meiosis: evidence from the synthesis and distribution of an acrosomal glycoprotein, acrogranin, during guinea pig spermatogenesis. Biology of reproduction 42: 317–328.
- 11. Ong CH, Bateman A (2003) Progranulin (granulin-epithelin precursor, PC-cell derived growth factor, acrogranin) in proliferation and tumorigenesis. Histology and histopathology 18: 1275–1288.
- 12. Tang W, Lu Y, Tian QY, Zhang Y, Guo FJ, et al. (2011) The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice. Science 332: 478–484.
- 13. Jian J, Konopka J, Liu C (2013) Insights into the role of progranulin in immunity, infection, and inflammation. Journal of leukocyte biology 93: 199–208.
- 14. Jian J, Zhao S, Tian Q, Gonzalez-Gugel E, Mundra JJ, et al. (2013) Progranulin directly binds to the CRD2 and CRD3 of TNFR extracellular domains. FEBS letters 587: 3428–3436.
- 15. Tian Q, Zhao Y, Mundra JJ, Gonzalez-Gugel E, Jian J, et al. (2014) Three TNFR-binding domains of PGRN act independently in inhibition of TNF-alpha binding and activity. Frontiers in bioscience (Landmark edition) 19: 1176–1185.
- 16. Li M, Liu Y, Xia F, Wu Z, Deng L, et al. (2014) Progranulin is required for proper ER stress response and inhibits ER stress-mediated apoptosis through TNFR2. Cellular signalling 26: 1539–1548.
- 17. Zhu J, Nathan C, Jin W, Sim D, Ashcroft GS, et al. (2002) Conversion of proepithelin to epithelins: roles of SLPI and elastase in host defense and wound repair. Cell 111: 867–878.
- 18. Kessenbrock K, Frohlich L, Sixt M, Lammermann T, Pfister H, et al. (2008) Proteinase 3 and neutrophil elastase enhance inflammation in mice by inactivating antiinflammatory progranulin. The Journal of clinical investigation 118: 2438–2447.
- 19. Egashira Y, Suzuki Y, Azuma Y, Takagi T, Mishiro K, et al. (2013) The growth factor progranulin attenuates neuronal injury induced by cerebral ischemia– reperfusion through the suppression of neutrophil recruitment. Journal of neuroinflammation 10: 105.
- 20. Kawase R, Ohama T, Matsuyama A, Matsuwaki T, Okada T, et al. (2013) Deletion of progranulin exacerbates atherosclerosis in ApoE knockout mice. Cardiovascular research 100: 125–133.
- 21. Vezina A, Vaillancourt-Jean E, Albarao S, Annabi B (2014) Mesenchymal stromal cell ciliogenesis is abrogated in response to tumor necrosis factor-alpha and requires NF-kappaB signaling. Cancer letters 345: 100–105.
- 22. Zhao YP, Tian QY, Liu CJ (2013) Progranulin deficiency exaggerates, whereas progranulin-derived Atsttrin attenuates, severity of dermatitis in mice. FEBS letters 587: 1805–1810.
- 23. Guo Z, Li Q, Han Y, Liang Y, Xu Z, et al.. (2012) Prevention of LPS-induced acute lung injury in mice by progranulin. Mediators of inflammation: 540794.
- 24. Qiu F, Song L, Ding F, Liu H, Shu Q, et al. (2013) Expression level of the growth factor progranulin is related with development of systemic lupus erythematosus. Diagnostic pathology 8: 88.
- 25. Tanaka A, Tsukamoto H, Mitoma H, Kiyohara C, Ueda N, et al. (2012) Serum progranulin levels are elevated in patients with systemic lupus erythematosus, reflecting disease activity. Arthritis research & therapy 14: R244.
- 26. Yamamoto Y, Takemura M, Serrero G, Hayashi J, Yue B, et al.. (2014) Increased Serum GP88 (Progranulin) Concentrations in Rheumatoid Arthritis. Inflammation.
- 27. Miller ZA, Rankin KP, Graff-Radford NR, Takada LT, Sturm VE, et al. (2013) TDP-43 frontotemporal lobar degeneration and autoimmune disease. Journal of neurology, neurosurgery, and psychiatry 84: 956–962.
- 28. De Riz M, Galimberti D, Fenoglio C, Piccio LM, Scalabrini D, et al. (2010) Cerebrospinal fluid progranulin levels in patients with different multiple sclerosis subtypes. Neuroscience letters 469: 234–236.
- 29. Thurner L, Preuss KD, Fadle N, Regitz E, Klemm P, et al. (2013) Progranulin antibodies in autoimmune diseases. Journal of autoimmunity 42: 29–38.
- 30. Thurner L, Stoger E, Fadle N, Klemm P, Regitz E, et al.. (2014) Proinflammatory Progranulin Antibodies in Inflammatory Bowel Diseases. Digestive diseases and sciences.
- 31. Thurner L, Zaks M, Preuss KD, Fadle N, Regitz E, et al. (2013) Progranulin antibodies entertain a proinflammatory environment in a subgroup of patients with psoriatic arthritis. Arthritis research & therapy 15: R211.
- 32. Yin F, Banerjee R, Thomas B, Zhou P, Qian L, et al. (2010) Exaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice. The Journal of experimental medicine 207: 117–128.
- 33. Feng J, Guo F, Jiang B, Zhang Y, Frenkel S, et al. (2010) Granulin epithelin precursor: a bone morphogenic protein 2-inducible growth factor that activates Erk1/2 signaling and JunB transcription factor in chondrogenesis. FASEB Journal 24: 1879–1892.
- 34. Curotto de Lafaille MA, Lafaille JJ (2009) Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor? Immunity 30: 626–635.
- 35. Fantini MC, Becker C, Monteleone G, Pallone F, Galle PR, et al. (2004) Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. J Immunol 172: 5149–5153.
- 36. Shevach EM (2002) CD4+ CD25+ suppressor T cells: more questions than answers. Nature reviews 2: 389–400.
- 37. Yamano Y, Takenouchi N, Li HC, Tomaru U, Yao K, et al. (2005) Virus-induced dysfunction of CD4+CD25+ T cells in patients with HTLV-I-associated neuroimmunological disease. The Journal of clinical investigation 115: 1361–1368.
- 38. Wexler EM, Rosen E, Lu D, Osborn GE, Martin E, et al. (2011) Genome-wide analysis of a Wnt1-regulated transcriptional network implicates neurodegenerative pathways. Science signaling 4: ra65.
- 39. Rosen EY, Wexler EM, Versano R, Coppola G, Gao F, et al. (2011) Functional genomic analyses identify pathways dysregulated by progranulin deficiency, implicating Wnt signaling. Neuron 71: 1030–1042.
- 40. Bluestone JA, Hebrok M (2008) Safer, longer-lasting regulatory T cells with beta-catenin. Nature medicine 14: 118–119.
- 41. Maddur MS, Othy S, Hegde P, Vani J, Lacroix-Desmazes S, et al.. (2010) Immunomodulation by intravenous immunoglobulin: role of regulatory T cells. Journal of clinical immunology Suppl 1: S4–8.
- 42. Kessel A (2007) Ammuri H (2007) Peri R (2007) Pavlotzky ER (2007) Blank M, et al. (2007) Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. Journal of immunology 179: 5571–5575.
- 43. Ephrem A (2008) Chamat S (2008) Miquel C (2008) Fisson S (2008) Mouthon L, et al. (2008) Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood 111: 715–722.
- 44. Bayry J (2012) Mouthon L (2012) Kaveri SV (2012) Intravenous immunoglobulin expands regulatory T cells in autoimmune rheumatic diseases. The journal of rheumatology 39: 450–451.
- 45. Trinath J (2013) Hegde P (2013) Sharma M (2013) Maddur MS (2013) Rabin M, et al. (2013) Intravenous immunoglobulin expands regulatory T cells via induction of cycooxygenase-2-dependent prostaglandin E2 in human dendritic cells. Blood 122: 1419–1427.
- 46. Bayry J, Sibéril S (2007) Triebel F (2007) Tough DF (2007) Kaveri SV (2007) Rescuing CD4+CD25+ regulatory T-cell functions in rheumatoid arthritis by cytokine-targeted monoclonal antibody therapy. Drug discovery today 12: 548–552.
- 47. He Z, Ismail A, Kriazhev L, Sadvakassova G, Bateman A (2002) Progranulin (PC-cell-derived growth factor/acrogranin) regulates invasion and cell survival. Cancer research 62: 5590–5596.
- 48. Van Damme P, Van Hoecke A, Lambrechts D, Vanacker P, Bogaert E, et al. (2008) Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival. The Journal of cell biology 181: 37–41.
- 49. Xu J, Xilouri M, Bruban J, Shioi J, Shao Z, et al.. (2011) Extracellular progranulin protects cortical neurons from toxic insults by activating survival signaling. Neurobiology of aging 32: : 2326 e2325–2316.
- 50. Sato A, Yamamoto H, Sakane H, Koyama H, Kikuchi A (2010) Wnt5a regulates distinct signalling pathways by binding to Frizzled2. The EMBO journal 29: 41–54.
- 51. Hu Y, Xiao H, Shi T, Oppenheim JJ, Chen X (2014) Progranulin promotes tumour necrosis factor-induced proliferation of suppressive mouse CD4(+) Foxp3(+) regulatory T cells. Immunology 142: 193–201.
- 52. Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, et al. (2004) Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. The Journal of experimental medicine 200: 277–285.
- 53. Valencia X, Stephens G, Goldbach-Mansky R, Wilson M, Shevach EM, et al. (2006) TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood 108: 253–261.
- 54. Zanin-Zhorov A, Ding Y, Kumari S, Attur M, Hippen KL, et al. (2010) Protein kinase C-theta mediates negative feedback on regulatory T cell function. Science (New York, NY 328: 372–376.
- 55. Nie H, Zheng Y, Li R, Guo TB, He D, et al. (2013) Phosphorylation of FOXP3 controls regulatory T cell function and is inhibited by TNF-alpha in rheumatoid arthritis. Nature medicine 19: 322–328.
- 56. Miyara M, Ito Y, Sakaguchi S (2014) T-cell therapies for autoimmune rheumatic diseases. Nat Rev Rheumatol.
- 57. Lan Q, Fan H, Quesniaux V, Ryffel B, Liu Z, et al. (2012) Induced Foxp3(+) regulatory T cells: a potential new weapon to treat autoimmune and inflammatory diseases? Journal of molecular cell biology 4: 22–28.